Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World watch: timing of myeloma relapse under the microscope

NCT ID NCT04985643

Knowledge-focused Sponsor: Takeda Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study observes 357 people with multiple myeloma to see how long it takes for the disease to come back after their first treatment. Participants visit their clinic every 3 months and receive standard care. The goal is to better understand relapse timing in real-life practice, without testing any new treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

357 people

The number who actually took part.

Started

Feb 2022

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study will enroll participants who have a confirmed diagnosis of MM in clinical sites located in the Russian Federation.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. With newly diagnosed multiple myeloma (NDMM) eligible and non-eligible for a high-dose therapy and autologous stem cell transplantation (HDT-ASCT) who have had a response (defined as CR, VGPR, or PR) to the ongoing SoC induction (1st line) therapy that has been started within 3 months before the inclusion. 2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 at the time of inclusion. Exclusion Criteria: 1. With NDMM eligible and non-eligible for a HDT-ASCT who have had SD or PD to the ongoing standard of care (SoC) induction (1st line) therapy that has been started within 3 months before the inclusion. 2. Current, previous (within the last year) or planned (for the next 15-20 months) participation in interventional clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple myeloma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple myeloma

Contacts and locations

Locations

  • Altai Regional Clinical Hospital

    Barnaul, Altayskiy Kray, 656024, Russia

  • BaltikMed Clinic

    Kaliningrad, Northwestern Federal District, 238022, Russia

  • City Clinical Hospital No. 1 named after prof. S.I.Sergeev

    Khabarovsk, Far Eastern Federal District, 680009, Russia

  • City Clinical Hospital No. 12

    Nizhny Novgorod, Volga Federal District, 603003, Russia

  • City Clinical Hospital No. 31

    Saint Petersburg, Sankt-Peterburg, 197110, Russia

  • Clinic Akademicheskaya LLC

    Volgograd, Volgogradskaya District, 400001, Russia

  • District Clinical Hospital

    Khanty-Mansiysk, Tyumen Oblast, 628012, Russia

  • GUZ "Lipetsk City Hospital No. 3" Free Falcon "

    Lipetsk, Lipetsk Oblast, 398007, Russia

  • Herzen Moscow Scientific Research Oncological Institute

    Moscow, Moscow Oblast, 125284, Russia

  • Kaluga Regional Clinical Hospital

    Kaluga, Central Federal District, 248007, Russia

  • Kirov Research Institute of Hematology and Blood Transfusion

    Kirov, Kirov Oblast, 610027, Russia

  • Moscow Regional Research Clinical Institute n.a. M.F. Vladimirsky

    Moscow, Moscow Oblast, 129110, Russia

  • National Research Center of Hematology of the Ministry of Health

    Moscow, Moscow Oblast, 125167, Russia

  • Novosibirsk State Medical University, Department of Therapy, Hematology and Transfusiology based on City Clinical Hospital No. 2

    Novosibirsk, Novosibirsk Oblast, 630051, Russia

  • Orenburgskaya Regional Clinical Hospital n.a. V.I. Voinova

    Orenburg, Orenburgskaya District, 460018, Russia

  • Razumovskiy Saratov State Medical University, University Clinical

    Saratov, Saratov Oblast, 410028, Russia

  • Republican Clinical Hospital named after G.G. Kuvatov

    Ufa, 450005, Russia

  • Republican Clinical Hospital of the Ministry of Health of the Republic of Tatarstan

    Kazan', Republic Tatarstan, 420064, Russia

  • Republican hospital named after V.A.Baranov

    Petrozavodsk, Republic of Karelia, 185019, Russia

  • Smolensk Clinical Hospital of Russian Railways-Medicine

    Smolensk, Central Federal District, 214025, Russia

  • Surgut Regional Clinical Hospital

    Surgut, Tyumen Oblast, 628408, Russia

  • Tomsk Regional Clinical Hospital

    Tomsk, Siberian Federal District, 634063, Russia

  • Ulyanovsk Regional Clinical Hospital

    Ulyanovsk, Ulyanovsk Oblast, 432017, Russia

  • Vologda Regional Clinical Hospital

    Vologda, Northwestern Federal District, 160002, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.